For healthRX comparison guide, the useful starting point is not whether the internet is excited about it. It is whether the evidence, safety limits, prescription pathway, and follow-up plan are strong enough to support a real patient decision.
Last fall, a patient I work with (I’ll call her Dana) sat down at her follow-up visit and set two vials on the table, side by side. One was a Wegovy pen her endocrinologist had prescribed before the shortage hit. The other was a compounded semaglutide vial she’d been using for the past twelve weeks through a telehealth program. Same molecule. Same dose in milligrams. Same injection site on her abdomen every Thursday morning. Her A1C trajectory hadn’t budged between the two. “So what exactly am I comparing here?” she asked. It’s the right question, and the answer is less dramatic than most online comparisons make it sound.
The Boring Truth About the Comparison
Compounded semaglutide and brand-name Ozempic or Wegovy contain the same active pharmaceutical ingredient. Full stop. They are not two different drugs competing for your attention like Coke and Pepsi. The molecule is semaglutide in both cases.
What differs is everything around the molecule: the supply pathway, the manufacturing process, the regulatory category, the labeling, the excipients in the vial, and sometimes the dose granularity. The brand-name finished products are FDA-approved and backed by large registrational trials (STEP, SUSTAIN). Compounded preparations are not FDA-approved as finished products and have not been studied as finished products in those same trials.
That asymmetry matters, but it needs to be understood precisely. It’s a regulatory and evidentiary distinction, not a molecular one. A serious comparison treats these as separate variables instead of lumping them into “brand good, compounded sketchy” or the equally lazy inverse.
What the Clinical Trials Actually Showed
The evidence base for semaglutide as a weight-loss and metabolic drug is strong, and it was built entirely on the brand-name finished product.
STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention. The semaglutide arm lost approximately 14.9% of body weight from baseline versus 2.4% in the placebo arm (Wilding et al., New England Journal of Medicine, 2021). Individual responders ranged widely, but the group-level effect was substantial. STEP-3 layered on intensive behavioral therapy and pushed the effect a bit further in the same direction. STEP-5 extended follow-up to 104 weeks and showed the weight reduction held in the active arm.
On the diabetes side, the SUSTAIN program established glycemic and cardiovascular benefits at lower doses (0.5 mg and 1.0 mg weekly, with 2.0 mg added later in SUSTAIN FORTE). SUSTAIN-6, the cardiovascular outcome trial, showed a reduction in major adverse cardiovascular events in a high-risk diabetes population (Marso SP et al.).
Because the active ingredient is the same, the underlying pharmacology of compounded semaglutide is identical. GLP-1 receptor agonism, glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, appetite reduction through hypothalamic signaling: all of that tracks the molecule, not the label on the box. But the finished-product data belongs to the finished product. You can reasonably infer from molecule to compounded preparation. You cannot say the STEP trials proved that a specific compounded vial works identically. That’s the honest framing.
Dosing, Titration, and the Details That Actually Affect Your Week
The Wegovy label calls for a five-step titration: 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then the maintenance dose of 2.4 mg. Full escalation takes about sixteen weeks if you stick to four weeks per step.
Most compounded programs use the same milligram increments. Where they differ is in the concentration of the solution and the volume you draw into the syringe. This trips people up. A patient switching programs might see a completely different volume for the same dose. The dose in milligrams is what matters clinically, not whether you’re drawing 0.1 mL or 0.25 mL.
The schedule is also not a forced march. Someone battling persistent nausea at 0.5 mg can camp there for an extra four weeks (or longer) before stepping up. Someone doing well clinically at 1.7 mg can stay put rather than pushing to 2.4 mg. This is a clinical decision, not a compliance checkbox.
Day-to-day, the operational details that shape experience are injection-site rotation (abdomen, thigh, upper arm), refrigerated storage at 36 to 46°F, and dose timing. Pick a day, stick with it, rotate your sites. That’s about it.
Side Effects: The GI Gauntlet and Beyond
The dominant side-effect category is gastrointestinal. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These were reported consistently across the STEP and SUSTAIN programs and show up just as reliably in real-world use. Most events are mild to moderate, cluster in the first eight to twelve weeks, and ease with continued therapy or a temporary pause on dose escalation.
Less common but important: gallbladder events (especially with rapid weight loss), acute pancreatitis (rare, but needs prompt evaluation if you develop severe abdominal pain radiating to the back), and a theoretical signal for thyroid C-cell tumors based on rodent data that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent thyroid finding and a contraindication for patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because the insulin effect is glucose-dependent. The risk rises when semaglutide is stacked with insulin or sulfonylureas, which is the diabetes setting, and the fix there is adjusting the other medication, not necessarily stopping semaglutide.
The safety profile of compounded semaglutide is expected to track the brand-name profile because the molecule is the same. The catch is that adverse-event reporting for compounded preparations runs through state pharmacy boards and voluntary MedWatch submissions, which is a less complete dataset than the structured post-marketing surveillance system around an FDA-approved product. This doesn’t mean compounded semaglutide is less safe. It means the surveillance net has wider holes.
The Money Part
Brand-name Wegovy and Ozempic carry list prices north of $1,300 per month in the U.S. Cash-pay at most retail pharmacies lands somewhere in the $1,000 to $1,400 range. Insurance coverage for the weight-management indication is inconsistent (to put it charitably). The diabetes indication has better coverage but varies meaningfully by plan.
Compounded programs in compliant telehealth structures price well below that. HealthRX, for example, runs $179.99 to $279.99 per month depending on dose, is available in 44 states, and operates under LegitScript certification.
The pricing gap is real and structural. Brand-name products carry the cost of industrial manufacturing, regulatory submissions, post-marketing surveillance infrastructure, and the commercial margin that funds the next generation of trials. Compounded preparations are produced at a different scale through a different regulatory pathway. Think of it like the difference between a mass-produced pharmaceutical and a made-to-order preparation from a licensed pharmacy. Different economics, different cost structure.
But cost is not the whole comparison. A patient with generous insurance coverage might pay less for brand-name Wegovy than for a compounded program. A patient without coverage might pay five or six times more for the brand-name product. The right framing is individual.
How to Actually Evaluate a Compounded Program
Two questions cut through most of the noise. First: what is the source pharmacy, and does it have a clean inspection history? This is verifiable information. State pharmacy boards maintain inspection records. Programs that publish their source pharmacy and invite you to check are behaving differently from programs that don’t.
Second: what is the clinical structure? Is a licensed prescriber reviewing your intake, ordering labs where appropriate, and scheduling follow-ups at a reasonable cadence? Or is the “consultation” a five-question form that rubber-stamps a shipment?
Those two questions, honestly answered, screen out a meaningful percentage of programs that shouldn’t be in the conversation. The HealthRX comparison guide walks through this in more detail, including the trial context that informs practical dosing and safety decisions. It’s not a substitute for talking to your own clinician, but it’s the kind of background reading that makes that conversation sharper.
My genuinely opinionated take: the biggest risk in the compounded semaglutide space is not the molecule. It’s fly-by-night programs with no real clinical oversight that treat semaglutide like a commodity widget to be shipped as fast as possible. A well-run compounded program with a reputable 503A pharmacy and actual prescriber follow-up is a fundamentally different product from a gray-market operation, even though both say “compounded semaglutide” on the label.
See also: The Role of Technology in Financial Services (FinTech)
When to Pick Up the Phone
Several situations call for a real conversation with your prescriber or a trip to urgent care rather than waiting for your next scheduled check-in:
Persistent severe abdominal pain, especially with radiation to the back or fever. Inability to keep fluids down for more than 24 hours, signs of dehydration, persistent vomiting. New gallbladder symptoms (right upper quadrant pain after meals, jaundice). New or worsening reflux that doesn’t respond to meal-timing adjustments. Mood changes, including new depressive symptoms.
Pregnancy, planned pregnancy, or breastfeeding: have the conversation before your next dose. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication that should have been caught at intake. If it wasn’t, that’s an urgent call.
Patients on insulin, sulfonylureas, warfarin, or other narrow-therapeutic-window medications should be in active communication with their prescriber about how semaglutide’s effects (particularly slowed gastric emptying) interact with those regimens.
Frequently Asked Questions
If the active ingredient is the same, is the effect the same?
The pharmacological effect is expected to track the active ingredient. But compounded preparations have not been studied as finished products in registrational trials. The STEP and SUSTAIN data belong to the brand-name finished product. You can reasonably infer. You cannot claim proof.
Why would a clinician prescribe compounded rather than brand-name?
Most commonly: cost, access during brand-name supply shortages, and the ability to individualize the preparation (smaller starting doses, for example) in ways the labeled product doesn’t formally accommodate.
Is compounded semaglutide legal?
Compounding under section 503A of the FFDCA is a regulated pathway when performed by a state-licensed pharmacy under a valid prescription. The legal landscape for the broader category has shifted depending on whether the brand-name product is on the FDA shortage list at a given time.
How do I evaluate a specific compounded program?
Look at the source pharmacy, the prescriber licensing structure, the intake and follow-up cadence, and any independent certifications such as LegitScript. Programs that publish these details transparently are easier to vet than programs that keep them vague.
What about quality variation between compounding pharmacies?
Quality varies. Patients are better served by programs that name their source pharmacy and work with pharmacies that have clean state inspection histories and, where applicable, 503B outsourcing facility status.
Can I switch between compounded and brand-name semaglutide?
Yes, but confirm the milligram dose at the transition. The volume and concentration will differ. Your prescriber should manage this with you.
Do I still need bloodwork or follow-ups on a compounded program?
Any program worth using will include baseline labs and periodic follow-ups. If a program ships medication without meaningful clinical oversight, that itself is a red flag.
References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).
Important Notice
Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.
